ATE324881T1 - Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen - Google Patents

Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen

Info

Publication number
ATE324881T1
ATE324881T1 AT01961984T AT01961984T ATE324881T1 AT E324881 T1 ATE324881 T1 AT E324881T1 AT 01961984 T AT01961984 T AT 01961984T AT 01961984 T AT01961984 T AT 01961984T AT E324881 T1 ATE324881 T1 AT E324881T1
Authority
AT
Austria
Prior art keywords
disubstituted
methods
trans
antagonists
therapeutic agents
Prior art date
Application number
AT01961984T
Other languages
English (en)
Inventor
Ibert C Wells
Original Assignee
Magnesium Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magnesium Diagnostics Inc filed Critical Magnesium Diagnostics Inc
Application granted granted Critical
Publication of ATE324881T1 publication Critical patent/ATE324881T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01961984T 2000-08-09 2001-08-09 Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen ATE324881T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/635,266 US6455734B1 (en) 2000-08-09 2000-08-09 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states

Publications (1)

Publication Number Publication Date
ATE324881T1 true ATE324881T1 (de) 2006-06-15

Family

ID=24547100

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01961984T ATE324881T1 (de) 2000-08-09 2001-08-09 Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen

Country Status (9)

Country Link
US (12) US6455734B1 (de)
EP (1) EP1355638B1 (de)
JP (1) JP2004508299A (de)
AT (1) ATE324881T1 (de)
AU (1) AU2001283203A1 (de)
CA (1) CA2418951A1 (de)
DE (1) DE60119385D1 (de)
NZ (1) NZ523915A (de)
WO (1) WO2002011714A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171093A1 (en) * 1999-03-10 2004-09-02 Wells Ibert C. Methods for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
US6372440B2 (en) * 1999-03-10 2002-04-16 Magnesium Diagnostics, Inc. Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
CA2637312A1 (en) 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL142416B (nl) * 1969-04-30 1974-06-17 Univ Osaka Werkwijze voor het bereiden van 6-amino-acylaminopenicillanzuren, alsmede werkwijze voor de bereiding van farmaceutische preparaten.
US4073913A (en) 1974-11-08 1978-02-14 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4097472A (en) 1974-11-08 1978-06-27 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
FR2166316A1 (en) * 1972-01-07 1973-08-17 Toyama Chemical Co Ltd 7-acylcephalosporins - prepd via a silylated inter
IL42124A (en) 1972-05-02 1977-02-28 Kabi Ab Substrate for the determination of proteolytic enzymes
US3894995A (en) 1972-12-26 1975-07-15 Hoechst Ag Transparent polyamides from an isomeric mixture of norbornanes
US3885136A (en) * 1974-02-25 1975-05-20 Gulf & Western Industries Reset timer/counter unit
US4201863A (en) 1974-11-08 1980-05-06 Mitsubishi Chemical Industries, Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4144244A (en) 1977-12-27 1979-03-13 Ciba-Geigy Corporation Perfluoroalkyl-iodo norbornane dicarboxylic acids and derivatives thereof
US4304771A (en) 1979-07-13 1981-12-08 Usv Pharmaceutical Corporation Antihypertensive amides
US4352751A (en) 1979-09-10 1982-10-05 Analytical Radiation Corporation Species-linked diamine triacetic acids and their chelates
US4331570A (en) 1980-07-17 1982-05-25 International Flavors & Fragrances Inc. Carboamidoalkyl norbornanes and organoleptic use in perfumes
US4532342A (en) 1981-02-20 1985-07-30 Warner-Lambert Company N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
AU564576B2 (en) * 1981-09-24 1987-08-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Purine derivatives
US4609661A (en) * 1982-08-09 1986-09-02 Syntex (U.S.A.) Inc. Substituted 9-(1-O- or 3-O-monosubstituted or 1,3-di-O-substituted propoxymethyl)purines as antiviral agents
DE3401949A1 (de) 1984-01-20 1985-08-01 Bayer Ag, 5090 Leverkusen Norbornan- und norbornencarbonsaeureamide, verfahren zu deren herstellung sowie die verwendung von norbornan- und norbornencarbonsaeureamiden als arzneimittel
US4761481A (en) 1985-03-18 1988-08-02 Baxter Travenol Laboratories, Inc. Substituted pyridine derivatives
DE8517666U1 (de) * 1985-06-18 1985-08-14 Heinrich Baumgarten KG, Spezialfabrik für Beschlagteile, 5908 Neunkirchen Geschirrgriff für die Befestigung an Bolzen
US4705897A (en) 1986-05-05 1987-11-10 Texaco Inc. Process for producing bicyclic diamines
US4772607A (en) 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
GB8613431D0 (en) 1986-06-03 1986-07-09 Medical Res Council Human tachykinins
IL83966A (en) 1986-09-26 1992-03-29 Schering Ag Amides of aminopolycarboxylic acids and pharmaceutical compositions containing them
GB2200115B (en) * 1987-01-21 1990-11-14 Sandoz Ltd Novel peptide derivatives, their production and use
US4792555A (en) 1987-03-20 1988-12-20 American Home Products Corporation Phospholipase A2 inhibitors
US5128346A (en) 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
DE3804793A1 (de) 1988-02-16 1989-08-24 Hoechst Ag Renin-hemmende aminosaeurederivate
CA1328333C (en) 1988-03-04 1994-04-05 Quirico Branca Amino acid derivatives
US5256645A (en) 1988-03-04 1993-10-26 Hoffmann-La Roche Inc. Amino acid derivatives
CA1330613C (en) 1988-05-06 1994-07-05 Masanori Kawamura Amino acid derivatives
US5177089A (en) * 1988-06-01 1993-01-05 Eisai Co., Ltd. Butenoic or propenoic acid derivative
CA1340588C (en) 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
JPH0225417A (ja) * 1988-07-12 1990-01-26 Asahi Chem Ind Co Ltd 抗潰瘍剤
FR2640970A1 (en) * 1988-12-28 1990-06-29 Pf Medicament "Z"-1-Phenyl-2-(aminomethyl)cyclopropanecarboxamide derivatives and their therapeutic application
US5049548A (en) * 1989-03-03 1991-09-17 Merck & Co., Inc. Renin-inhibitory di-, tri-, and tetrapeptides
US5616562A (en) 1990-04-27 1997-04-01 Murphy; Christopher J. Methods and compositions using substance P to promote wound healing
AU687754B2 (en) 1990-08-31 1998-03-05 Warner-Lambert Company Tachykinin antagonists
IE920175A1 (en) 1991-02-11 1992-08-12 Zeneca Ltd Nitrogen heterocycles
FR2676734B1 (fr) 1991-05-23 1995-05-19 Roussel Uclaf Nouveaux derives de la pyrimidine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP0532466A3 (en) * 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
US5527790A (en) * 1991-09-30 1996-06-18 The University Of British Columbia Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar
JP3122520B2 (ja) 1992-03-13 2001-01-09 生化学工業株式会社 ２−アミノピリジン誘導体、その製造方法及び蛍光標識剤
JP2578044B2 (ja) 1992-03-14 1997-02-05 呉羽化学工業株式会社 フェニルアラニン−グリシン誘導体、その製造方法、及びその誘導体を含有する抗腫瘍剤
US5506227A (en) 1992-04-13 1996-04-09 Merck Frosst Canada, Inc. Pyridine-substituted benzyl alcohols as leukotriene antagonists
US5641783A (en) 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
JP3548205B2 (ja) * 1993-10-29 2004-07-28 キヤノン株式会社 画像処理方法およびその装置
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
CA2109684C (en) * 1993-11-22 2002-03-19 Peter A. Pubben Faucet control device
US5492927A (en) 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
ITFI940009A1 (it) 1994-01-19 1995-07-19 Menarini Farma Ind Antagonisti delle tachichinine, loro preparazione e formulazioni farmaceutiche che li contengono.
US5646155A (en) 1994-05-12 1997-07-08 University Of Massachusetts Medical Center Drugs to prevent recurrent herpes virus infections
ES2165915T3 (es) 1994-06-06 2002-04-01 Warner Lambert Co Antagonistas del receptor de la taquiquinina (nk 1).
US5491140A (en) 1994-06-30 1996-02-13 Eli Lilly And Company Naphthyl tachykinin receptor antagonists to treat physiological conditions
TW307746B (de) * 1994-10-14 1997-06-11 Sumitomo Chemical Co
ES2218554T3 (es) 1994-10-27 2004-11-16 Fujisawa Pharmaceutical Co., Ltd. Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina.
US5607947A (en) 1995-02-21 1997-03-04 Eli Lilly And Company Pyrrolidinyl tachykinin receptor antagonists
US5563133A (en) 1995-02-21 1996-10-08 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
WO1997011940A1 (en) 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
AU7475396A (en) * 1995-10-30 1997-05-22 Merck & Co., Inc. Novel inhibitors of peptide binding to mhc class ii proteins
CA2191924A1 (en) * 1995-12-05 1997-06-06 Kevin Felsenstein 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of .beta.-amyloid protein production
JP4357001B2 (ja) 1996-04-23 2009-11-04 ターガセプト，インコーポレイテッド 中枢神経系障害の予防及び治療のための医薬組成物
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US5703173A (en) * 1996-08-16 1997-12-30 Integument Technologies, Inc. Transition metallohalopolymers
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
EP0882717B1 (de) 1996-10-01 2010-09-08 Kyowa Hakko Kirin Co., Ltd. Stickstoff enthaltende heterocyclische verbindungen
WO1998021184A1 (en) 1996-11-14 1998-05-22 Pfizer Inc. Process for substituted pyridines
JPH10177774A (ja) 1996-12-16 1998-06-30 Fujitsu Ltd ディスク装置及び携帯型電子装置
CO4920227A1 (es) * 1996-12-17 2000-05-29 Warner Lambert Co Histidina-n-bencil glicinamida sustituida con cicloalquilos .
US6559144B2 (en) 1997-02-13 2003-05-06 Merck Patent Gesellschaft Mit Bicyclic amino acids
DE69818248T2 (de) 1997-04-22 2004-06-17 Janssen Pharmaceutica N.V. Chinolin- und chinazolin-derivate als crf antagonisten
US6180632B1 (en) 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6172084B1 (en) 1997-06-19 2001-01-09 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
EP1032377B1 (de) * 1997-11-21 2010-11-17 Purdue Neuroscience Company Substituierte 2-aminoacetamide und anwendung davon
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
US6011066A (en) * 1998-02-02 2000-01-04 Veterans General Hospital-Taipei Method for treating septic shock
US6133455A (en) * 1998-02-09 2000-10-17 American Cyanamid Company Process for the preparation of 2-aryl-5(perfluoro-alkyl) pyrrole compounds from N-(arylmethylene)-1-chloro-1-(perfluoroalkyl) methylamine compounds
US6689754B1 (en) 1998-04-10 2004-02-10 G. D. Searle & Co. Heterocyclic glycyl β-alanine derivatives
SK16742000A3 (sk) * 1998-05-12 2001-07-10 Warner-Lambert Company Kombinácie proteínovej farnesyltransferázy a inhibítorov hmg coa reduktázy a ich použitie pri liečbe rakoviny
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
MY125037A (en) 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6090942A (en) 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
TWI243192B (en) * 1998-12-31 2005-11-11 Ciba Sc Holding Ag Phthalimidyl azo pigments, method for producing same and utilization thereof
EP1159273A1 (de) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Verbindungen, verwendbar als reversible inhibitoren von cathepsin s
AT407993B (de) * 1999-03-03 2001-07-25 Voest Alpine Ind Anlagen Verfahren zur optimierung von auslegung und betrieb eines reduktionsverfahrens
US6372440B2 (en) 1999-03-10 2002-04-16 Magnesium Diagnostics, Inc. Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
EP1165500A1 (de) 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amidderivate als inhibitoren von matrix metalloproteinasen, tnf-alpha und aggrecanase
SG82692A1 (en) * 1999-04-07 2001-08-21 Sumitomo Chemical Co Method for purifying beta-phenylethyl alcohol
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US20020169101A1 (en) * 1999-05-10 2002-11-14 Gonzalez Maria Isabel Treatment of sexual dysfunction
JP2001079018A (ja) * 1999-09-14 2001-03-27 Gc Corp 歯科用自動切削加工装置
US6369729B1 (en) * 1999-10-08 2002-04-09 Cirrus Logic, Inc. Common mode shift in downstream integrators of high order delta sigma modulators
WO2001040192A1 (en) * 1999-12-03 2001-06-07 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
JP2003516974A (ja) 1999-12-17 2003-05-20 カイロン コーポレイション グリコーゲンシンターゼキナーゼ３のピラジンベースインヒビター
US6328386B1 (en) * 2000-01-11 2001-12-11 Takata Seat Belts Inc. Seat belt system
US6656958B2 (en) 2000-02-02 2003-12-02 Abbott Laboratories Substituted pyridine compounds useful for controlling chemical synaptic transmission
US6593340B1 (en) * 2000-02-28 2003-07-15 Cv Technologies, Inc. Pharmaceutical compositions containing N-propargylphentermine and related analogs to treat neurodegeneration and/or depression
DE60102137T2 (de) 2000-03-17 2004-10-21 Bristol Myers Squibb Pharma Co Beta-aminsäure-derivate zur verwendung als matrix-metalloproteasen- und tna-alpha-inhibitoren
EP1288202A4 (de) * 2000-05-11 2003-07-02 Banyu Pharma Co Ltd N-acyltetrahydroisochinolin-derivate
US6539771B1 (en) * 2000-05-12 2003-04-01 Delphi Technologies, Inc. Seat sensor calibration method and system
US20030087915A1 (en) 2000-05-12 2003-05-08 Dull Gary Maurice Pharmaceutical compositions and methods for use
EP1283855B1 (de) * 2000-05-23 2005-11-02 Dyomics GmbH Stabile nir-marker-farbstoffe auf der basis von benzopyrylium-polymethinen
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6583153B2 (en) 2000-12-12 2003-06-24 Ortho-Mcneil Pharmaceutical, Inc. 7-heterocyclyl quinoline and thieno[2,3-b]yridine derivatives useful as antagonists of gonadotropin releasing hormone
US6943250B2 (en) * 2001-03-06 2005-09-13 Fmc Corporation Protected aminofunctionalized polymerization initiators and methods of making and using same
US7276523B2 (en) 2001-03-30 2007-10-02 Smithkline Beecham Corporation Aminopyridine derivatives as estrogen receptor modulators
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
WO2002092087A1 (en) 2001-05-11 2002-11-21 Vertex Pharmaceuticals Incorporated 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
CA2463770A1 (en) 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
US6635771B2 (en) * 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
KR100447255B1 (ko) 2001-12-31 2004-09-07 주식회사 하이닉스반도체 입자 함침층 조성물 및 이를 이용한 연마 패드
AU2003211093A1 (en) 2002-02-15 2003-09-09 The Regents Of The University Of Michigan Inhibitors of rgs proteins
US7235558B2 (en) 2002-06-06 2007-06-26 Sanofi-Aventis Deutschland Gmbh Inhibitors of the GPIb—vWF interaction, their preparation and use
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004052373A1 (en) 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k

Also Published As

Publication number Publication date
US6855826B2 (en) 2005-02-15
EP1355638A2 (de) 2003-10-29
US7041829B2 (en) 2006-05-09
US7132537B2 (en) 2006-11-07
US20070010535A1 (en) 2007-01-11
US20110021633A1 (en) 2011-01-27
WO2002011714A3 (en) 2003-08-14
US8129545B2 (en) 2012-03-06
US20030040625A1 (en) 2003-02-27
US7982048B2 (en) 2011-07-19
CA2418951A1 (en) 2002-02-14
JP2004508299A (ja) 2004-03-18
US20070197659A1 (en) 2007-08-23
AU2001283203A1 (en) 2002-02-18
US20110281923A1 (en) 2011-11-17
US6455734B1 (en) 2002-09-24
US20060069259A1 (en) 2006-03-30
US6664420B2 (en) 2003-12-16
WO2002011714A2 (en) 2002-02-14
EP1355638B1 (de) 2006-05-03
DE60119385D1 (de) 2006-06-08
US7619097B2 (en) 2009-11-17
US20100048711A1 (en) 2010-02-25
US20050096279A1 (en) 2005-05-05
NZ523915A (en) 2005-05-27
US20120142781A1 (en) 2012-06-07
US20040110692A1 (en) 2004-06-10
US7795450B2 (en) 2010-09-14
US7405311B2 (en) 2008-07-29
US20090030080A1 (en) 2009-01-29
US7211667B2 (en) 2007-05-01

Similar Documents

Publication Publication Date Title
EA200501798A1 (ru) Новые пептиды, которые связываются с рецептором к эритропоэтину
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
EA200500782A1 (ru) Лечение геморрагического шока
DE69429527D1 (de) Inhibitoren von beta-amyloid-protein-herstellung
NO20055852L (no) Nye peptider som binder til erytropoietinreseptoren
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
EA200501710A1 (ru) Замещённые карбоновые кислоты
EA200401365A1 (ru) Способы лечения илеуса
NO20010446L (no) Substituert anilidforbindelser og metoder
EA199900669A1 (ru) Промежуточные соединения для получения замещенных n-[аминоиминометил или аминометил)фенил]пропиламидов
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
ATE420654T1 (de) Behandlung von muskeldystrophien und verwandter erkrankungen
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
DE602004031356D1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
BG101867A (bg) Бензотиазиндиоксиди като антагонисти на ендотелин
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
DE60140707D1 (de) GSK3-Polypeptide
ATE324881T1 (de) Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
NO20030155L (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
ATE435649T1 (de) 4-brom-5-(2-chlor-benzoylamino)-1h-pyrazol-3- carbonsäure(phenyl)amid-derivate und verwandte verbindungen als bradykinin b1 receptor antagonisten zur behandlung von entzündlichen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties